ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding ArriVent BioPharma, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 68 | 1 | 80 | +13 |
| Shares | 25.9M | 1.47K | 28.5M | +2.56M (+9.9%) |
| Value | $612.3M | $33.9K | $757.5M | +$145.2M (+23.7%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (24)
Institutions that held ArriVent BioPharma, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (11)
Institutions that held ArriVent BioPharma, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Perceptive Advisors LLC | 415,000 | $9.75M |
| Marshall Wace, LLP | 85,250 | $2.00M |
| Ghisallo Capital Management LLC | 50,000 | $1.18M |
| Saturn V Capital Management LLC | 47,266 | $1.11M |
| AlphaCentric Advisors LLC | 15,000 | $352.5K |
| Qube Research & Technologies Ltd | 11,354 | $266.8K |
| Jane Street Group, LLC | 10,626 | $249.7K |
| D. E. Shaw & Co., Inc. | 8,775 | $206.2K |
| STRS Ohio | 1,700 | $40.0K |
| Capital Performance Advisors LLP | 67 | $1.57K |
| Ronald Blue Trust, Inc. | 39 | $723 |
Not filed for Q4 2024 yet (1)
Institutions that held ArriVent BioPharma, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Rakuten Investment Management, Inc. | 1,474 | $33.9K |